Sagimet Biosciences Inc Ordinary Shares - Series A SGMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.65
- Day Range
- $7.34–8.10
- 52-Week Range
- $4.50–11.41
- Bid/Ask
- $7.51 / $8.05
- Shares Outstanding
- 61.75M
- Market Cap
- $482.90M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.sagimet.com
Valuation
|
Metric
|
SGMT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.49 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SGMT
|
|---|---|
Quick Ratio | 19.74 |
Current Ratio | 20.34 |
Interest Coverage | — |
Quick Ratio
SGMT
Profitability
|
Metric
|
SGMT
|
|---|---|
Return on Assets (Normalized) | −28.84% |
Return on Equity (Normalized) | −30.47% |
Return on Invested Capital (Normalized) | −34.78% |
Return on Assets
SGMT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$!wh?h | LOCK|PJW? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K@WSH$y | LOCK|?dksJ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|P$W$?jj | LOCK|XX | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|j?Z<js | LOCK|n^ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&hG<q? | LOCK|%p?G | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|VdgRrY@ | LOCK|g#%W | $26B | |||
| Moderna Inc
MRNA
| LOCK|#n$hkQQ | LOCK|@k | $25B | |||
| Incyte Corp
INCY
| LOCK|>f!dlgx | LOCK|f^J | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|kzVrPyn | LOCK|>Q> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?^h^FV@ | LOCK|%%d | $16B |
United States